Background

Lucid dreams are frequently pleasant and training techniques have been developed to teach dreamers to induce them. In addition, the induction of lucid dreams has also been used as a way to ameliorate nightmares. On the other hand, lucid dreams may be associated with psychiatric conditions, including Post-Traumatic Stress Disorder (PTSD) and Reward Deficiency Syndrome-associated diagnoses. In the latter conditions, lucid dreams can assume an unpleasant and frequently terrifying character.
Case Presentations

We present two cases of dramatic alleviation of terrifying lucid dreams in patients with PTSD. In the first case study, a 51-year-old, obese woman, diagnosed with PTSD and depression, had attempted suicide and experienced terrifying lucid nightmares linked to sexual/physical abuse from early childhood by family members including her alcoholic father. Her vivid “bad dreams” remained refractory in spite of 6 months of treatment with Dialectical Behavioral Therapy (DBT) and standard pharmaceutical agents which included prazosin, clonidie and Adderall. The second 39-year-old PTSD woman patient had also suffered from lucid nightmares.
Results

The medication visit notes reveal changes in the frequency, intensity and nature of these dreams after the complex putative dopamine agonist KB220Z was added to the first patient’s regimen. The patient reported her first experience of an extended period of happy dreams. The second PTSD patient, who had suffered from lucid nightmares, was administered KB220Z to attenuate methadone withdrawal symptoms and incidentally reported dreams full of happiness and laughter.
Conclusions

These cases are discussed with reference to the known effects of KB220Z including enhanced dopamine homeostasis and functional connectivity of brain reward circuitry in rodents and humans. Their understanding awaits intensive investigation involving large-population, double-blinded studies.

Synaptose KB220Z Neuroadaptogen Neuronutrient Complex ingredients:
DL-Phenylalanine (D-PhenEze™)
L-Tyrosine
Passion Flower Extract (EM103™) (3.5% Vitexin)
Metallosaccharide™ Complex
Arabinogalactans
N-Acetylglucosamine
Astragalus (root)
Aloe Vera (inner leaf)
Indian Frankincense
Gum Resin
White Pine Bark Extract
Spirulina (Zehntose™)
Rhodiola root extract (3% Rosavins) (RhodiGen™)
L-Glutamine
5-Hydroxytroptophan (5-HTP)
Thiamine Hydrochloride
Pyroxidal-5-Phosphate
Pyridoxine HCI
Chromium Polynicotinate (ChromeMate®)

Drugs in the LSD family, including psilocybin and tryptamines actually stimulate REM sleep (in doses small enough to allow sleep), leading to longer REM periods.

http://www.google.com/patents/US20040266659

Ufo - Thanks for digging that up. The paper is written as if DB220Z is a specific, novel compound. Seems kind of dodgy to me

Blessings
~ND

putative dopaminergic effects of nutmeg

Which is funny, because DL-Phen never produced any LD for me, even in 700mg doses.

Have you tried it with any other protein source? Because there seems to be some sort of competition going on...idk how it works exactly...but dl-phenylalanine without anything else has noticable psychoactivity for me even in small doses while it doesn't do anything if taken as whey protein for instance...

Background

Lucid dreams are frequently pleasant and training techniques have been developed to teach dreamers to induce them. In addition, the induction of lucid dreams has also been used as a way to ameliorate nightmares. On the other hand, lucid dreams may be associated with psychiatric conditions, including Post-Traumatic Stress Disorder (PTSD) and Reward Deficiency Syndrome-associated diagnoses. In the latter conditions, lucid dreams can assume an unpleasant and frequently terrifying character.
Case Presentations

We present two cases of dramatic alleviation of terrifying lucid dreams in patients with PTSD. In the first case study, a 51-year-old, obese woman, diagnosed with PTSD and depression, had attempted suicide and experienced terrifying lucid nightmares linked to sexual/physical abuse from early childhood by family members including her alcoholic father. Her vivid “bad dreams” remained refractory in spite of 6 months of treatment with Dialectical Behavioral Therapy (DBT) and standard pharmaceutical agents which included prazosin, clonidie and Adderall. The second 39-year-old PTSD woman patient had also suffered from lucid nightmares.
Results

The medication visit notes reveal changes in the frequency, intensity and nature of these dreams after the complex putative dopamine agonist KB220Z was added to the first patient’s regimen. The patient reported her first experience of an extended period of happy dreams. The second PTSD patient, who had suffered from lucid nightmares, was administered KB220Z to attenuate methadone withdrawal symptoms and incidentally reported dreams full of happiness and laughter.
Conclusions

These cases are discussed with reference to the known effects of KB220Z including enhanced dopamine homeostasis and functional connectivity of brain reward circuitry in rodents and humans. Their understanding awaits intensive investigation involving large-population, double-blinded studies.

Wiki says, Myristicin is anticholinergic.